Presant C A, Bartolucci A A
Cancer. 1982 May 15;49(10):2192-6. doi: 10.1002/1097-0142(19820515)49:10<2192::aid-cncr2820491035>3.0.co;2-r.
Two hundred seventy-seven evaluable patients with metastatic malignant melanoma without prior chemotherapy were entered into combination chemotherapy drug trials in the Southeastern Cancer Study Group during the period between 1974-1978. In order to determine which prognostic factors were favorable for response to chemotherapy and for survival, an analysis was performed utilizing a logistic regression equation. Significant favorable prognostic variables for complete or partial tumor regression included no involvement of lung (P = 0.045), no involvement of liver (P = 0.08), and possibly, receiving treatment schedule 361B of Table 1 (P = 0.093). It was notable that sex and initial performance status were not significant factors. Significant favorable prognostic variables for survival included high initial performance status (P less than 0.001), no involvement of liver (P = 0.005), sex-female (P = 0.056), and bone involvement only (P = 0.057); lack of brain involvement as a favorable factor was of only marginal statistical associated with survival. These data indicate stratification which should be considered in future therapeutic trials, and identify factors which may influence clinical decision making in palliative management of patients with metastatic malignant melanoma.
1974年至1978年间，277例未经前期化疗的转移性恶性黑色素瘤可评估患者进入了东南部癌症研究组的联合化疗药物试验。为了确定哪些预后因素有利于化疗反应和生存，利用逻辑回归方程进行了分析。肿瘤完全或部分消退的显著有利预后变量包括无肺部受累（P = 0.045）、无肝脏受累（P = 0.08），以及可能接受表1中的治疗方案361B（P = 0.093）。值得注意的是，性别和初始体能状态不是显著因素。生存的显著有利预后变量包括高初始体能状态（P＜0.001）、无肝脏受累（P = 0.005）、女性（P = 0.056）以及仅骨受累（P = 0.057）；缺乏脑受累作为有利因素与生存仅具有边缘统计学关联。这些数据表明了在未来治疗试验中应考虑的分层情况，并确定了可能影响转移性恶性黑色素瘤患者姑息治疗临床决策的因素。
